Results 71 to 80 of about 38,364 (253)
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota +14 more
wiley +1 more source
ABSTRACT The use of medicinal products derived from cannabis and its synthetic analogues has grown in recent years for various health conditions, which led to an increase in systematic reviews (SR) on the topic. The objective of this overview was to identify, synthesize, and critically appraise the evidence from SR on the benefits and harms of cannabis
Rafael Leite Pacheco +5 more
wiley +1 more source
Policy Points The liberalization of medical and recreational cannabis policies may increase cannabis initiation across age groups, with increased prevalence of cannabis use among young adults and adults and weaker effects among youth. Evidence also suggests increases in cannabis‐related health care utilization among adults.
SARAH B. WINDLE +8 more
wiley +1 more source
Opportunities and Alliances: The Relational Dynamics of Criminal Collusion in Latin America
ABSTRACT Based on ethnographic fieldwork in Mexico and judicial wiretap analysis in Argentina, this paper shows that collusion between state actors and violent non‐state actors operates through fluid and competitive relational networks rather than stable hierarchies or fixed institutional arrangements.
Eldad J. Levy, Javier Auyero
wiley +1 more source
Cannabis use and mood disorders: a systematic review
BackgroundProblematic cannabis use is highly prevalent among people with mood disorders. This underscores the need to understand the effects of cannabis and cannabinoids in this population, especially considering legalization of recreational cannabis use.
Maryam Sorkhou +4 more
doaj +1 more source
Anastasia Suraev,1– 3 Llewellyn Mills,4,5 Sarah V Abelev,1 Thomas R Arkell,6 Nicholas Lintzeris,4,5,* Iain S McGregor1– 3,* 1The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Sydney, NSW, Australia; 2The University of ...
Suraev A +5 more
doaj
Electroconvulsive Therapy and Time to Psychiatric Readmission in Schizophrenia
ABSTRACT Introduction There is evidence that electroconvulsive therapy (ECT) can augment the effects of antipsychotics in schizophrenia. However, there is limited evidence from Western populations on whether ECT reduces the risk of relapse compared to non‐ECT treatment in schizophrenia.
Linnea Stenmark +2 more
wiley +1 more source
Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour +4 more
wiley +1 more source
IntroductionCannabis is Europe's most commonly used illicit drug. Some users do not develop dependence or other problems, whereas others do. Many factors are associated with the occurrence of cannabis-related disorders.
Matthijs Blankers +6 more
doaj +1 more source
Cannabis use, harms and the management of cannabis use disorder
Cannabis is the most widely used illicit drug in the world, with the highest rates of use seen in New Zealand, North America and Australia. There is evidence of a decrease in the age of commencement of cannabis use in some developed countries, and a prolongation of risk of initiation to cannabis use beyond adolescence in more recent cohorts of users ...
Jan Copeland +2 more
openaire +1 more source

